Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 9/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 8/20 | 0.48 |
| ▸ | CA1 | P00915 | 8/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552089 | 1.00 | CYP2D6 (0.57) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL12237522 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL19861473 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL6788287 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL12281867 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL25083758 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL130217 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL6788279 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL1776767 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL8671879 | 0.95 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699979-B2 | PREPARED VIA A STEREOSPECIFIC SN2 NUCLEOPHILIC ATTACK OF A PHOSPHODIESTER, OR PHOSPHOROTHIOATE, ON THE 3' POSITION OF A XYLONUCLEOTIDE; USEFUL IN ANTISENSE OR PROBE TECHNOLOGY | ISIS PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| US-6500945-B2 | BIOSYNTHESIS; STEREOSPECIFIC | ISIS PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | COOK PHILLIP DAN (US) | 2002-09-26 | — | — | US | disclosed |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. | 2001-07-19 | — | — | US | disclosed |
| US-6239265-B1 | FOR RESEARCH AND DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-6087482-A | INTER-SUGAR LINKAGES ARE FOUR ATOM LINKING GROUPS; FOR IMPROVED NUCLEASE RESISTANCE AND CELLULAR UPTAKE; FOR DIAGNOSIS AND ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-5852188-A | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5677437-A | MACROMOLECULES; REGULATING RNA EXPRESSION; THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0655088-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994022886-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993008296-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | CYP2D6 2289/4885THRB 3154/4885HSD17B10 4394/4885 |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | CYP2D6 2289/4885THRB 3154/4885HSD17B10 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.